Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenues:
Clinical treatment programs	$ 42	$ 72
Total revenues	42	72
Costs and expenses:
Production/cost of goods sold	191	280
Research and development	2,336	1,665
General and administrative	2,077	1,874
Total costs and expenses	4,604	3,819
Operating loss	(4,562)	(3,747)
Interest expense	(5)	(11)
Interest and other income	181	273
Funds received from sale of income tax net operating losses	686	1,328
Redeemable warrants valuation adjustment	89	(151)
Net loss	(3,611)	(2,308)
Other Comprehensive Income (Loss):
Unrealized gain on marketable securities	45	397
Realized loss on securities	(10)	(16)
Less: Premium amortization	1	60
Net comprehensive loss	$ (3,575)	$ (1,867)
Basic and diluted loss per share (usd per share)	$ (0.02)	$ (0.02)
Weighted average shares outstanding, basic and diluted (shares)	166,806,729	135,787,466